drugset / Trial / NCT00297713

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

NCT00297713

Phase 2 Completed 12 enrolled Altus Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults and children. ALTU-238 is designed to require fewer injections than the currently available formulations of rhGH.

Timeline

Start
2005-07
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic

Indications